Immunogenicity of Danish-SSI 1331 BCG vaccine in the UK: comparison with Glaxo-Evans 1077 BCG vaccine (Q39029013)

8 September 2017

Immunogenicity of Danish-SSI 1331 BCG vaccine in the UK: comparison with Glaxo-Evans 1077 BCG vaccine (English)

1 reference

8 September 2017

1 reference

12

1 reference

8 September 2017

Patricia Gorak-Stolinska

1

1 reference

8 September 2017

Rosemary E Weir

2

1 reference

8 September 2017

Sian Floyd

3

1 reference

8 September 2017

Maeve K Lalor

4

1 reference

8 September 2017

Sally Stenson

5

1 reference

8 September 2017

Keith Branson

6

1 reference

8 September 2017

Rose Blitz

7

1 reference

8 September 2017

Sarah Luke

8

1 reference

8 September 2017

Bernadette Nazareth

9

1 reference

8 September 2017

Anne Ben-Smith

10

1 reference

8 September 2017

Paul E M Fine

11

1 reference

8 September 2017

language of work or name

English

0 references

publication date

8 May 2006

1 reference

8 September 2017

1 reference

8 September 2017

24

1 reference

8 September 2017

29-30

1 reference

8 September 2017

5726-5733

1 reference

BCG vaccination of schoolchildren in England and Wales

8 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.037

BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.037

Effectiveness of BCG vaccination in England and Wales in 1983.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.037

Comparison of the Efficacy of Liquid and Freeze-dried Strains of B.C.G. Vaccine in Preventing Tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.037

BCG vaccine-associated suppurative lymphadenitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.037

BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.037

Interferon-gamma and skin test responses of schoolchildren in southeast England to purified protein derivatives from Mycobacterium tuberculosis and other species of mycobacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.037

Does bacille Calmette-Guérin scar size have implications for protection against tuberculosis or leprosy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.037

Patterns and implications of naturally acquired immune responses to environmental and tuberculous mycobacterial antigens in northern Malawi.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.037

Evaluation of BCG vaccines in children, the effect of strain and dose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.037

A comparative study of Danish (Statens Seruminstitut), Glaxo and Behringwerke vaccines--revaccination of schoolchildren.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.037

In vitro cellular and cytokine responses to mycobacterial antigens: application to diagnosis of tuberculosis infection and assessment of response to mycobacterial vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.037

Diagnosis of tuberculosis based on the two specific antigens ESAT-6 and CFP10.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.037

Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.037

A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.037

Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.037

Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.037

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.037

Correlates of protective immunity to Mycobacterium tuberculosis in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.037

Tuberculosis subunit vaccine development: on the role of interferon-γ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.037

Investigation of the relationships between immune-mediated inhibition of mycobacterial growth and other potential surrogate markers of protective Mycobacterium tuberculosis immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.037

Preclinical testing of new vaccines for tuberculosis: a comprehensive review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.037

Comparative genomics of BCG vaccines by whole-genome DNA microarray

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.037

Identification of substrains of BCG vaccine using multiplex PCR

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.037

Correlation between BCG genomics and protective efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.037

The impact of changing BCG coverage on tuberculosis incidence in Swedish-born children between 1969 and 1989

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.037

Variation in protection by BCG: implications of and for heterologous immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.037

10.1016/J.VACCINE.2006.04.037

7 January 2021

Identifiers

DOI

1 reference

8 September 2017

1 reference